tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Pompeo A et al. Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells. 1999 Life Sci. pmid:10096434
Nogueira JM et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. 1999 Transplantation pmid:10096529
Shapiro R et al. Posttransplant diabetes in pediatric recipients on tacrolimus. 1999 Transplantation pmid:10096540
Hemenway CS and Heitman J Calcineurin. Structure, function, and inhibition. 1999 Cell Biochem. Biophys. pmid:10099825
Holländer GA et al. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. 1994 Transfus Sci pmid:10155542
Antoniou EA et al. Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. 1999 Microsurgery pmid:10188834
Yasutsune T et al. Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. 1999 Br. J. Pharmacol. pmid:10188984
Zhang W et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. 1999 Circ. Res. pmid:10189360
Fansa H et al. The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. 1999 J Hand Surg Br pmid:10190602
Meiser BM et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. 1999 J. Heart Lung Transplant. pmid:10194038
Azuma N et al. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. 1999 J. Vasc. Surg. pmid:10194498
Mollison KW et al. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. 1998 Curr. Pharm. Des. pmid:10197049
De Lima JJ et al. Effects of FK506 in rat and human resistance arteries. 1999 Kidney Int. pmid:10201018
Sloper CM et al. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. 1999 Ophthalmology pmid:10201592
Nagasaki Y et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. 1999 Pediatr. Res. pmid:10203136
Hortelano S et al. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. 1999 Br. J. Pharmacol. pmid:10205001
Cetinkale O et al. Modulating the functions of neutrophils and lipid peroxidation by FK506 in a rat model of thermal injury. 1999 Burns pmid:10208383
Lütkes P et al. [Quality of life following transplantation. The impact ofa new immunosuppressive substance]. 1999 Zentralbl Chir pmid:10209841
Jani A et al. Modulation of cell-mediated immunity prolongs adenovirus-mediated transgene expression in sciatic nerve. 1999 Hum. Gene Ther. pmid:10210146
Knoll GA and Bell RC Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. 1999 BMJ pmid:10213717
Green MD and Michaels MG Tacrolimus: effects and side effects. 1999 Pediatr. Infect. Dis. J. pmid:10223694
Ferrari D et al. P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. 1999 J. Biol. Chem. pmid:10224077
Herr I et al. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. 1999 Brain Res. pmid:10224298
Charco R et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. 1999 Liver Transpl Surg pmid:10226111
Taylor DO et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. 1999 J. Heart Lung Transplant. pmid:10226898
Torocsik HV et al. FK506-induced leukoencephalopathy in children with organ transplants. 1999 Neurology pmid:10227644
Göthel SF and Marahiel MA Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. 1999 Cell. Mol. Life Sci. pmid:10228556
Uno T et al. Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. 1999 Lipids pmid:10230718
Johnston A and Holt DW Therapeutic drug monitoring of immunosuppressant drugs. 1999 Br J Clin Pharmacol pmid:10233195
Vente C et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. 1999 Br. J. Dermatol. pmid:10233234
Lyon CC et al. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. 1999 Br. J. Dermatol. pmid:10233300
Jolles S et al. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. 1999 Br. J. Dermatol. pmid:10233301
Mollison KW et al. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. 1999 J. Invest. Dermatol. pmid:10233764
Akahane M et al. Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. 1999 J. Bone Miner. Res. pmid:10234577
Stratta RJ et al. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. 1999 Ann. Surg. pmid:10235529
Remy I and Michnick SW Clonal selection and in vivo quantitation of protein interactions with protein-fragment complementation assays. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10318894
Genazzani AA et al. Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10318964
Morioka M et al. Activities of calcineurin and phosphatase 2A in the hippocampus after transient forebrain ischemia. 1999 Brain Res. pmid:10320733
Ferlicot S et al. [Smooth muscle mesentery associated with Epstein-Barr virus (EBV). Report of a case in a child with a liver transplant under FK506 regimen]. 1999 Ann Pathol pmid:10320913
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Garrity ER et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. 1999 J. Heart Lung Transplant. pmid:10328140
Ruzicka T et al. Tacrolimus: the drug for the turn of the millennium? 1999 Arch Dermatol pmid:10328199
Schmidt RH et al. Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. 1999 Nephrol. Dial. Transplant. pmid:10328486
Kohyama T et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. 1999 Mol. Cell Biol. Res. Commun. pmid:10329481
Tian J and Karin M Stimulation of Elk1 transcriptional activity by mitogen-activated protein kinases is negatively regulated by protein phosphatase 2B (calcineurin). 1999 J. Biol. Chem. pmid:10329725
Nakamura H et al. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. 1999 J. Allergy Clin. Immunol. pmid:10329849
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Okamoto H The CD38-cyclic ADP-ribose signaling system in insulin secretion. 1999 Mol. Cell. Biochem. pmid:10331647
Iwamoto H et al. Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. 1999 Graefes Arch. Clin. Exp. Ophthalmol. pmid:10333108
Henley SA et al. Lipids increase after solitary pancreas transplantation. 1999 Diabetes Care pmid:10333952